PDGFRB and neoplasm: Sorafenib is a multikinase inhibitor that targets the Raf/MAPK/ERK signaling pathway, interfering with the tyrosine kinases VEGFR-2/3, PDGFR-β, B-Raf, c-Raf, FGFR1, Flt3, c-KIT, RET, and p38 α, and induces tumor cell apoptosis in HCC [19,20].